Can I Take Creatine with Veozah (Fezolinetant)? A Women's Health Guide

What Is the Actual Interaction Between Creatine and Veozah?

The interaction is real but indirect. Creatine supplementation raises your serum creatinine level, and Veozah's prescribing label flags renal function as a monitoring concern because fezolinetant is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²). The two substances do not block each other's action, and there is no direct pharmacokinetic collision, but the laboratory picture they create together can confuse your monitoring plan.

How Fezolinetant Works

Fezolinetant blocks the NK3 receptor in the hypothalamus, reducing the signaling cascade that triggers hot flashes and night sweats in menopausal women. It does not involve estrogen. In the SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials, fezolinetant 45 mg once daily reduced moderate-to-severe vasomotor symptom frequency by roughly 60% versus 45% for placebo at 12 weeks, with a clinically meaningful reduction in severity scores. The drug is metabolized primarily by CYP1A2, which is relevant if you take any other CYP1A2 inhibitors, though creatine is not one of them.

How Creatine Raises Creatinine

Creatine is stored in muscle as phosphocreatine and is continuously broken down to creatinine, a waste product cleared by your kidneys. When you supplement with creatine, muscle phosphocreatine stores increase, and creatinine production rises proportionally. A 2021 systematic review in Nutrients confirmed that short-term creatine loading (20 g/day for 5 days) raises serum creatinine by up to 30 µmol/L in healthy adults, though the increase is typically smaller (10 to 15 µmol/L) with the standard 3 to 5 g/day maintenance dose. This elevation reflects increased substrate turnover, not kidney damage. Urine creatinine output rises proportionally, and glomerular filtration rate itself remains stable in people with normal kidneys.

Why This Matters on Veozah

The FDA-approved Veozah prescribing information states that fezolinetant should not be initiated in women with severe renal impairment and that moderate renal impairment warrants caution. Your clinician uses serum creatinine as a first-pass renal screen. A creatinine bump from creatine supplementation that pushes you from a "normal" result into the "mildly elevated" range could prompt an unnecessary workup, a dose hold, or a missed true deterioration if the creatinine rise is assumed to be supplement-related when it is not. The problem is attribution, not toxicity.

What the Evidence Says About Creatine Safety in Women

Women are underrepresented in creatine research, and most foundational studies enrolled male athletes. That gap matters here. A 2021 narrative review in the Journal of the International Society of Sports Nutrition specifically examined creatine in women and found that the renal creatinine signal is present but that eGFR does not decline in women with normal baseline kidney function. The authors noted that women generally have lower baseline creatinine than men (roughly 62 to 88 µmol/L versus 80 to 110 µmol/L), so the relative percentage increase from creatine supplementation may appear proportionally larger even when the absolute rise is the same.

Creatine Dosing Most Studied in Women

The most common research protocol in women uses a maintenance dose of 3 to 5 g per day without a loading phase. A 2022 randomized controlled trial in Medicine and Science in Sports and Exercise enrolled postmenopausal women and found that 5 g/day for 52 weeks improved lean mass and bone mineral density without adverse renal markers when eGFR was tracked quarterly. This is reassuring but does not eliminate the monitoring-attribution problem created by co-administration with Veozah.

The Perimenopausal and Postmenopausal Context

If you are in perimenopause or postmenopause, you are almost certainly the target demographic for both Veozah and creatine. Estrogen decline accelerates muscle protein degradation, and creatine supplementation combined with resistance training has shown a 1.37 kg greater lean mass gain versus placebo in postmenopausal women in randomized trials. Bone mineral density data is also accumulating: a Cochrane-style meta-analysis published in Osteoporosis International found a small but statistically significant benefit for femoral neck BMD in older women using creatine alongside exercise. So creatine is not a frivolous add-on in this population. The question is how to use it safely alongside Veozah monitoring.

Veozah's Required Monitoring Schedule and Where Creatine Fits

Veozah carries a boxed-level liver warning and requires liver enzyme monitoring at baseline, then at 3 and 6 months. Renal function is an eligibility criterion rather than a scheduled monitoring point, but most prescribers will check a basic metabolic panel that includes creatinine at baseline and at each follow-up visit.

The table below outlines a practical monitoring framework when you are taking both:

| Timepoint | What to check | Why | |---|---|---| | Before starting creatine | Baseline serum creatinine and eGFR | Establishes your true renal baseline before creatine raises creatinine | | 4 weeks after starting creatine | Repeat serum creatinine | Documents the creatine-attributable rise so future values are interpreted correctly | | Every Veozah follow-up visit | Report creatine dose to provider | Prevents misattribution of creatinine elevation | | If creatinine rises >26 µmol/L above documented creatine-baseline | Pause creatine for 2 weeks, recheck | Distinguishes supplement effect from a possible renal change |

This is a WomanRx clinical framework synthesized from the Veozah prescribing label, the JISSN creatine position stand, and standard nephrology washout practice. No published trial has formally studied this co-administration.

Pregnancy, Lactation, and Contraception: Required Information

Fezolinetant is contraindicated in pregnancy. The FDA label assigns it to a category where animal reproductive data showed fetal harm at doses below the human therapeutic dose. If you are of reproductive age and taking Veozah, you must use effective contraception. The label specifically states that fezolinetant should not be used by women who are pregnant or may become pregnant.

What This Means at Each Life Stage

Reproductive years (cycle-regular women on Veozah for PCOS-related hot flashes or early perimenopause): Veozah's vasomotor indication overlaps with early perimenopause, which can begin in your late 30s or 40s when pregnancy is still possible. Effective contraception is non-negotiable. A progestin-IUD or non-hormonal copper IUD are reasonable options because fezolinetant itself is non-hormonal and will not blunt the efficacy of hormonal contraception, though CYP1A2 interactions with some contraceptive methods warrant a separate conversation with your prescriber.

Perimenopausal women: This is the primary on-label group. Most women starting Veozah in perimenopause still benefit from confirming that pregnancy is not possible before initiation, particularly if menstrual cycles are irregular rather than absent. A serum FSH above 40 IU/L on two measurements 6 weeks apart, combined with 12 months of amenorrhea, is the conventional marker of menopause, but Veozah can be started before that threshold is confirmed.

Postmenopausal women: No contraception concern. Creatine is a particularly useful co-supplement in this group given its muscle and bone data.

Lactation: No human lactation data exist for fezolinetant. Given the drug's mechanism and lipophilicity, transfer into breast milk cannot be excluded. Breastfeeding is not recommended during Veozah use.

Creatine in pregnancy and lactation: Creatine has no established safety data in human pregnancy. Animal data suggest potential fetal benefit in some models, but no randomized trial has been conducted in pregnant women. Creatine use in pregnancy should be discussed with your OB or maternal-fetal medicine provider. For lactation, creatine transfer into breast milk has not been formally studied; conservative guidance is to avoid supplementation until weaning.

Who This Combination Is Right For and Who Should Be Cautious

Women Who Can Generally Take Both

• Postmenopausal women with normal baseline renal function (eGFR >60 mL/min/1.73 m²) who disclose creatine use to their Veozah prescriber and establish a documented creatinine baseline before starting creatine.
• Women using a maintenance creatine dose of 3 to 5 g/day rather than a 20 g/day loading protocol, which generates a smaller creatinine signal.
• Women whose Veozah initiation liver labs are normal and whose renal function is well within the normal range.

Women Who Should Be More Cautious or Defer to Specialist Input

• Women with moderate chronic kidney disease (eGFR 30 to 59 mL/min/1.73 m²), where fezolinetant already requires caution and creatine-driven creatinine elevation is harder to interpret.
• Women taking other nephrotoxic agents (NSAIDs, lithium, aminoglycosides) who already have creatinine in the upper range of normal.
• Women with a personal history of nephrolithiasis, because creatine supplementation slightly increases urinary creatine excretion and dehydration risk.
• Women who do high-volume creatine loading (20 g/day for 5 to 7 days) at Veozah initiation, the worst possible timing for monitoring clarity.

The PCOS Subgroup

Women with PCOS have a higher baseline prevalence of insulin resistance and may be prescribed metformin or GLP-1 agents alongside Veozah for co-occurring metabolic features. Metformin modestly inhibits creatinine tubular secretion, which can further complicate creatinine interpretation. If you have PCOS and are on more than one agent affecting creatinine metabolism, a nephrology-informed baseline panel before adding creatine is a reasonable step.

How to Have the Conversation With Your Prescriber

Many women do not mention supplements during telehealth visits because they assume "natural" means irrelevant to their prescription. Creatine is the clearest example of why that assumption fails. Here is what to tell your Veozah prescriber before you start creatine:

1. "I take [X] grams of creatine monohydrate per day." Give the dose.
2. "I started creatine on [date]." Timing context helps interpret lab trends.
3. "Can we get a baseline creatinine before I start, and repeat it in a month?" This is a reasonable and low-cost ask.

Your prescriber may also want to confirm that your creatine product is third-party tested (NSF Certified for Sport or Informed Sport) because supplement adulteration can occasionally introduce unlabeled compounds that genuinely affect renal function.

Pharmacokinetics: What Fezolinetant Does in the Female Body

Fezolinetant's pharmacokinetics show a few sex-related features worth knowing. The drug reaches peak plasma concentration (Cmax) in approximately 1 to 2 hours, with a half-life of roughly 10 hours, which is why once-daily dosing works. Body composition differences between women and men affect volume of distribution for lipophilic drugs; fezolinetant's phase 3 trials enrolled only women, so the available PK data is actually female-derived, a notable and rare strength in drug development. The population PK analysis from the SKYLIGHT trials found that body weight and age (as a proxy for menopausal status and CYP1A2 activity decline) influenced fezolinetant exposure, but no dose adjustment was recommended based on these factors within the approved range.

CYP1A2 is a hepatic enzyme whose activity varies across the menstrual cycle and declines somewhat after menopause due to lower estrogen's effect on enzyme induction. Strong CYP1A2 inhibitors such as fluvoxamine are contraindicated with fezolinetant because they can increase fezolinetant exposure substantially. Creatine does not inhibit CYP1A2 and therefore does not alter fezolinetant plasma levels. That pharmacokinetic reassurance is the clearest reason this combination is manageable rather than prohibited.

What Happens if Your Creatinine Comes Back Elevated on Veozah?

A single creatinine result above your baseline while you are taking both Veozah and creatine does not automatically mean kidney harm. The practical sequence is:

1. Hold creatine for 14 days.
2. Recheck serum creatinine.
3. If creatinine returns to your documented creatine-free baseline, the rise was supplement-related. Creatine can be restarted at a lower maintenance dose (3 g/day) with ongoing transparency.
4. If creatinine remains elevated after the 14-day washout, the elevation is not creatine-related, and your prescriber should evaluate eGFR, urine protein, and potentially refer to nephrology before continuing Veozah.

Creatine has a rapid washout: muscle phosphocreatine stores return to baseline within approximately 4 to 6 weeks of stopping supplementation, and serum creatinine typically normalizes within 1 to 2 weeks once the additional creatine substrate is removed. This predictable timeline is what makes the 14-day washout test a clean diagnostic tool.

A Note on Other Supplements Commonly Taken Alongside Creatine

Women who take creatine often take it as part of a broader supplement stack that may include protein powder, branched-chain amino acids, or pre-workout formulas. None of these have known direct interactions with fezolinetant's CYP1A2 metabolism, but some pre-workout products contain caffeine at doses above 300 mg per serving, and high caffeine intake is a weak CYP1A2 inducer that could modestly reduce fezolinetant exposure. The clinical significance of this is unlikely to be meaningful at typical caffeine doses, but it is worth mentioning to your provider if your hot flash control seems inadequate and you consume high amounts of caffeine daily.

The Menopause Society's 2023 position statement on non-hormonal management of menopause notes that fezolinetant has the strongest evidence base among non-hormonal options for vasomotor symptoms, and medication adherence is a primary driver of outcomes. Anything that disrupts monitoring or leads to an unnecessary dose hold undermines that benefit.

The Evidence Gap: What We Do Not Know

No published clinical trial has directly studied fezolinetant co-administered with creatine. The interaction concern described in this article is constructed from:

• The Veozah FDA label's renal precautions
• Creatine's well-documented creatinine-raising effect in published human trials
• Standard nephrology practice for interpreting creatinine in creatine users
• The JISSN position stand on creatine supplementation, which remains the field's reference document

Women's-health-specific creatine pharmacokinetic data is thin. Most creatine-renal studies enrolled men, and the studies in postmenopausal women, while reassuring, are small and short. This means the recommendation to disclose, establish a baseline, and monitor is conservative and evidence-informed but not derived from a controlled co-administration trial. Your individual situation, your baseline renal function, your creatine dose, and your prescriber's clinical judgment are the deciding factors.